Time to mandate data release and independent audits for all clinical trials

Haines, Ian E; Gabor Miklos, George L

doi:10.5694/mja11.10599

ARTICLE
AUTHORS
REFERENCES

As a condition of publication of phase III clinical trials, medical journals should insist on the release of all raw data and a written independent clinical audit

Editorials and commentaries in some high-profile journals herald an upcoming revolution in personalised oncology.1 However, any new treatment can only be considered an advance if it:

1 Medical Oncology and Palliative Care, Cabrini Health, Melbourne, VIC.
2 Secure Genetics, Sydney, NSW.

Correspondence: ian.haines@monash.edu

Competing interests:

No relevant disclosures.

1. Cancer: the revolution has begun [editorial]. Lancet 2010; 376: 1117.
2. Lemmens T. Leopards in the temple: restoring scientific integrity to the commercialized research scene. J Law Med Ethics 2004; 32: 641-657.
3. US Food and Drug Administration. FDA Briefing document Oncology Drug [sic] Advisory Committee Meeting. December 5, 2007. BLA STN 125085/91.018. Avastin (bevacizumab). http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4332b1-01-FDA.pdf (accessed Oct 2011).
4. D’Agostino RB Sr. Changing end points in breast-cancer drug approval — the Avastin story. N Engl J Med 2011; 365: e2.
5. Carpenter D, Kesselheim AS, Joffe S. Reputation and precedent in the bevacizumab decision. N Engl J Med 2011; 365: e3.
6. Ocana A, Amir E, Eisenhauer EA, et al. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011; 29: 254-256.
7. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
8. Haines IE, Miklos GLG. Paclitaxel plus bevacizumab for metastatic breast cancer [letter]. N Engl J Med 2008; 358: 1637-1638.
9. Miller KD, Chap LI, Holmes FA, et al. Randomised phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
10. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth-factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
11. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomised, double-blind, placebo-controlled, phase iii trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
12. Burstein HJ. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol 2011; 29: 1232-1235.
13. Pushing the envelope [editorial]. Nat Biotechnol 2011; 29: 669.
14. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
15. Roila F, Garassino MC, Ballatori E. Cetuximab for metastatic colorectal cancer [letter]. N Engl J Med 2009; 361: 95-97.
16. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
17. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3 randomised controlled trial. Lancet 2011; 377: 42-51.
18. Haines I, Elliott P, Stanley R. Rituximab-containing therapy for chronic lymphocytic leukaemia [letter]. Lancet 2011; 377: 205-206.
19. Haines I. Rituximab maintenance therapy for follicular lymphoma [letter]. Lancet 2011; 377: 1151-1152.
20. Friedberg JW. Rituximab maintenance in follicular lymphoma: PRIMA. Lancet 2011; 377: 4-6.
21. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135-1141.
22. Tannock I. 10-year analysis of the ATAC trial: wrong conclusion? Lancet Oncol 2011; 12: 216-217.
23. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
24. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumours. N Engl J Med 2011; 364: 514-523.
25. Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011; 12: 333-343.
26. de Boer RH, Arrieta Ó, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29: 1067-1074.
27. Pharmaceutical Benefits Scheme, Australian Government Department of Health and Ageing. PBS Schedule search. http://www.pbs.gov.au/pbs/search (accessed Oct 2011).
28. Pollack A. Approval for drug that treats melanoma. New York Times 2011; 25 Mar. http://www.nytimes.com/2011/03/26/business/26drug.html?_r=1 (accessed Oct 2011).
29. Katelaris AG. Research fraud — where to from here? Med J Aust 2011; 194: 619. <MJA full text>
30. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005; 2: e138.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Time to mandate data release and independent audits for all clinical trials

Author

Comment

Do you have any competing interests to declare? *